Cholinergic System Degeneration in Early and Prodromal Parkinson’s Disease
Overview
This study demonstrates significant degeneration of the nucleus basalis of Meynert (NbM) in early Parkinson’s disease (PD) and isolated REM sleep behaviour disorder (iRBD), a prodromal stage of PD. NbM volume reduction correlates with cognitive decline, symptom severity, and increased risk of dementia in PD, while also predicting phenoconversion risk in iRBD.
Background
Parkinson’s disease is a neurodegenerative disorder traditionally characterized by dopaminergic neuron loss but also involves degeneration of other neuromodulatory systems, including the cholinergic basal forebrain. Cognitive impairment is common in PD and can precede motor symptoms, with dementia developing in a majority of patients over time. The nucleus basalis of Meynert (NbM) is a key cholinergic nucleus implicated in cognitive functions such as attention and memory. Isolated REM sleep behaviour disorder (iRBD) is a prodromal condition strongly linked to future development of PD and related Lewy body disorders.
Data Highlights
Group
NbM Grey Matter Volume Change (β)
Significance (P)
Hazard Ratio for Dementia/Phenoconversion
Significance (P)
Early PD vs Controls
-12.56
0.003
<0.400
<0.004
iRBD vs Controls
-16.41
0.004
<0.490
0.016
Key Findings
NbM grey matter volume is significantly reduced in both early PD and iRBD compared to controls.
In PD, higher NbM volume correlates with better higher-order cognitive function and lower motor and non-motor symptom burden.
Reduced NbM volume in PD predicts increased risk of future dementia with a hazard ratio below 0.4.
In iRBD, higher NbM volume is associated with decreased risk of phenoconversion to PD or dementia with Lewy bodies.
Associations between NbM volume and clinical symptoms are less pronounced in iRBD despite similar volume deficits, suggesting compensatory mechanisms in prodromal stages.
Clinical Implications
NbM volume measured by structural MRI may serve as a valuable biomarker for identifying early PD patients at risk for cognitive decline and dementia, enabling targeted interventions. Additionally, NbM degeneration in iRBD patients could help predict phenoconversion to PD or Lewy body dementia, facilitating early diagnosis and monitoring. Understanding compensatory mechanisms in prodromal stages may open avenues for therapeutic strategies to delay disease progression.
Conclusion
The study highlights the critical role of cholinergic system degeneration, particularly NbM atrophy, in early and prodromal Parkinson’s disease. NbM volume is a promising biomarker for predicting cognitive decline and disease progression, with potential to improve clinical management and trial design.
References
Article Source 2024 -- Cholinergic System Degeneration in Early and Prodromal Stages of Parkinson’s Disease
by Tamir Eisenstein, Karolien Groenewald, Ludo van Hillegondsberg, Falah Al Hajraf, Tanja Zerenner, Michael A Lawton, Yoav Ben-Shlomo, Ludovica Griffanti, Michele T Hu, Johannes C Klein
